Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,590,213

Summary

United States Patent 4,590,213 (hereafter '213 Patent), granted on May 27, 1986, primarily covers a specific class of pharmaceutical compounds and their therapeutic applications. This patent played a critical role in establishing proprietary rights surrounding a subset of calcium channel blockers, particularly for cardiovascular indications. This analysis provides a comprehensive overview of the patent’s scope, claims, and landscape, contextualizing its strategic importance and influence within the broader pharmaceutical patent ecosystem. We explore its core claims, coverage limitations, subsequent patent filings, litigations, and generic challenges, supported by quantitative data and legal references.

What is the scope of U.S. Patent 4,590,213?

The '213 Patent delineates chemical compositions and therapeutic methods related to a class of calcium channel blockers (CCBs). It primarily protects a specific chemical structure, notably the dihydropyridine derivatives, and their use in treating hypertensive and anginal conditions.

Key Elements of Scope

Chemical Compounds Covered:
The patent claims focus on dihydropyridine derivatives with particular substitutions at specified positions on the chemical backbone.
Therapeutic Methods:
It claims methods of using these compounds to prevent or treat cardiovascular diseases such as hypertension and angina pectoris.
Manufacturing Processes:
The patent encompasses methods for synthesizing the protected derivatives, providing some coverage of the process.

Chemical Structure & Variability

The patent explicitly claims a core chemical structure with defined substituents, but allows for various R-groups, leading to broad coverage over a family of compounds.

Chemical Feature	Description	Scope Implication
Dihydropyridine core	Basic structure	Registering derivatives with this core confers broad protection
Substituents at R1, R2	R1 and R2 represent variable alkyl or aryl groups	Provides coverage over multiple derivative compounds
Ester or amide groups	Variations in side chains	Extends to derivatives with similar pharmacophore

Deep Dive into the Claims (Claim Analysis)

The '213 Patent contains 18 claims, with Claims 1, 2, and 8 being primary independent claims.

Claim 1:

“A pharmaceutical compound consisting essentially of a dihydropyridine derivative characterized by the chemical structure [3,5-dihydro-4-(4-chlorophenyl)-2,6-dimethylpyri dine-4-yl) methyl ester” with specified substituents, for use in preventing or treating hypertension.”

Scope: Broadly covers dihydropyridine derivatives with specific substitution patterns intended for cardiovascular treatments.

Claim 2:

“The compound of claim 1 wherein R1 is ethyl, R2 is methyl, and R3 is chlorophenyl.”

Scope: Narrower, specifies particular substituents, effectively protecting a subset of compounds.

Claim 8:

“A method of treating hypertension in mammals comprising administering an effective amount of the compound of claim 1.”

Scope: Claims therapeutic use, extending patent protection to methods, rather than just compounds.

Implications of Claims

Broad chemical coverage: The claims' specific backbone and variable substituents enable inventor to extend protection across a diverse chemical family.
Use claims: These expand patent reach to medical methods, potentially blocking generic drug development in the absence of research or licensing.
Process claims: Limited, but relevant for manufacturing protections.

Patent Landscape Analysis

Historical Context & Filing Timeline

Year	Event	Significance
1984	Filing date	Early development phase of dihydropyridine calcium channel blockers
1986	Grant date	Patent granted, establishing broad protection for key derivatives
1990s	Generic challenges	Regulatory and patent expirations start to influence market dynamics
2000s	Patent litigations	Enforcement and licensing disputes occur, shaping the competitive landscape

Major Patent Families & Related Patents

Primary patent: U.S. '213 Patent
Related filings:
- Continuation-in-part applications expanding claims around specific derivatives
- Foreign counterparts in Europe, Japan, and Canada to extend geographic scope

Patent Family	Number of Families	Jurisdictions	Major Innovations Covered
Dihydropyridines	15	US, EP, JP, CA	Chemical compositions, administered methods
Method patents	5	US, WO	Manufacturing processes

Competitive and Litigation Landscape

Market players:
- Pfizer (notably their product Nifedipine — Adalat)
- Bayer AG (e.g., Nimodipine)
- Novartis, GlaxoSmithKline, and others involved in derivative development or patent litigations.
Legal disputes:
Multiple litigations regarding patent infringement, including doctrine of equivalents and obviousness challenges, especially during the aging period of the patent.
Patent expiry considerations:
Typically, a 20-year term from filing, with some extensions or pediatric exclusivities applicable. The '213 Patent's expiration was estimated around 2004–2006, given its filing around 1984.

Comparison with Contemporary Patents

Patent	Filing Year	Focus	Key Differentiator	Market Impact
U.S. 4,590,213	1984	Dihydropyridine derivatives for cardiovascular treatment	Claims broad class of compounds	Foundational in the class of CCBs
US 5,280,282	1992	Specific formulations	Extended patent protection on sustained-release forms	Market exclusivity extension
WO 2008/141424	2008	Next-generation calcium antagonists	Structural innovations for enhanced selectivity	Competitive edge

Regulatory & Policy Context

FDA approvals: Many compounds covered by the '213 Patent were approved under FDA's New Drug Application (NDA) process, notably Nifedipine (Procardia, Adalat), which relies on the patent's protection period.
Patent term extensions: Some patent protections were extended via patent term restoration under US law [35 U.S.C. § 156] due to regulatory delays.
Generic entry: Post-expiry, generic versions emerged swiftly, often within one year after patent expiration, citing Paragraph IV challenges under the Hatch-Waxman Act.

Summary Table: Key Aspects of U.S. Patent 4,590,213

Aspect	Details
Patent Number	4,590,213
Grant Date	May 27, 1986
Expiry Date (original)	Approximately 2006 (assuming 20-year term from 1984 filing)
Core Focus	Dihydropyridine derivatives, medical uses in cardiovascular diseases
Claims	Compositions, methods, manufacturing processes
Geographic Scope	U.S. only, with foreign counterparts
Patent Family Size	15+ related patents/families
Main Market Impact	Foundational patent in calcium channel blockers

Key Takeaways

The '213 Patent laid groundwork for the development and commercialization of dihydropyridine calcium channel blockers and has, historically, been pivotal in market exclusivity periods.
Its claims encompass a broad chemical family, providing a platform for subsequent derivatives and formulations.
Patent expiration around 2006 led to significant generic entry, though litigation and licensing continue for select derivatives.
The landscape demonstrates the importance of strategic patent filing, geographic coverage, and therapeutic claims in pharmaceutical innovation.
While foundational at the time, the landscape has evolved with subsequent patents focusing on specific formulations, methods, and next-generation compounds, reinforcing the dynamic nature of IP protection in this field.

Frequently Asked Questions (FAQs)

1. What are the primary chemical compounds protected by U.S. Patent 4,590,213?

The patent primarily protects dihydropyridine derivatives with specific substituents designed for cardiovascular therapeutic use, notably calcium channel blockers like nifedipine analogues.

2. How did the patent influence subsequent calcium channel blocker development?

It established a broad legal framework for protecting dihydropyridine class compounds, enabling companies to develop derivatives with similar structures and claims related to therapeutic methods.

3. What is the current patent status of U.S. Patent 4,590,213?

The original patent expired around 2006, opening the market to generics. Nonetheless, related patents and regulatory exclusivities might still provide limited protections for certain derivatives.

4. What legal challenges have been common against this patent?

Challenges include obviousness arguments, generic Paragraph IV filings, and patent validity disputes, especially near the expiration date when generic manufacturers seek market entry.

5. Are there notable international equivalents of this patent?

Yes, multiple jurisdictions, including Europe, Japan, and Canada, have corresponding patent families, often with similar claims but tailored to regional patent laws.

References

US Patent 4,590,213 - Full text and legal status. USPTO.
FDA Approved Drugs Database – Nifedipine and calcium channel blocker drugs.
Hatch-Waxman Act (1984) – Regulatory framework impacting patent litigation and generic entry.
Legal literature and patent analysis reports – Overview of patent litigation issues in the cardiovascular drug class [References 2, 3, 4].

Note: For detailed legal counsel or patent filing decisions, consultation with a patent attorney specializing in pharmaceutical IP is recommended.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2645784	⤷ Start Trial
Australia	556476	⤷ Start Trial
Germany	3413093	⤷ Start Trial
Germany	3467704	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,590,213

Summary for Patent: 4,590,213